The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
ConclusionsRoxadustat has higher mean Hb level than placebo or EPO. Due to the short follow-up period and the lack of critical data, more RCTs are needed to prove long-term safety and effectiveness of roxadustat in the future.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Anemia | Cardiology | Databases & Libraries | Dialysis | Heart | Heart Failure | Iron | Stroke | Study | Urology & Nephrology